Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy

Brotons-Canto, Ana, Gamazo, Carlos, Martín-Arbella, Nekane, Abdulkarim, Muthanna, Gumbleton, Mark ORCID: https://orcid.org/0000-0002-7386-311X, Quincoces, Gemma, Peñuelas, Ivan and Irache, Juan M. 2019. Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy. Journal of Pharmaceutical Sciences 108 (7) , pp. 2421-2429. 10.1016/j.xphs.2019.02.022

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

Peanut allergy is one of the most prevalent and severe of food allergies with no available cure. The aim of this work was to evaluate the potential of an oral immunotherapy based on the use of a roasted peanut extract (PE) encapsulated in nanoparticles with immunoadjuvant properties. For this, a polymer conjugate formed by the covalent binding of mannosamine to the copolymer of methylvinyl ether and maleic anhydride was firstly synthetized and characterized. Then, the conjugate was used to prepare nanoparticles with an important capability to diffuse through the mucus layer and reach, in a large extent, the intestinal epithelium, including Peyer’s patches. Their immunotherapeutic potential was evaluated in a model of pre-sensitized CD1 mice to peanut. After completing therapy, mice underwent an intraperitoneal challenge with PE. Nanoparticle-treatment was associated with both less serious anaphylaxis symptoms and higher survival rates than control, confirming the protective effect of this formulation against the challenge.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Wiley
ISSN:	0022-3549
Date of First Compliant Deposit:	7 March 2019
Date of Acceptance:	27 February 2019
Last Modified:	19 Nov 2024 20:15
URI:	https://orca.cardiff.ac.uk/id/eprint/120346

Citation Data

Cited 11 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item